ABIOMED (ABMD) reported quarterly earnings results on Thursday, Jul-28-2016. The company said it had a profit of $0.29 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.05. Analysts had a consensus of $0.24. The company posted revenue of $103.00 million in the period, compared to analysts expectations of $97.48 million. The company’s revenue was up 40.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.
ABIOMED closed down -0.94 points or -0.81% at $115.03 with 8,28,104 shares getting traded on Thursday. Post opening the session at $116, the shares hit an intraday low of $112.05 and an intraday high of $116 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on Jul 1, 2016, Michael G Howley (VP, Global Sales & Marketing) sold 10,000 shares at $106.58 per share price. According to the SEC, on Jun 9, 2016, Andrew J Greenfield (VP Healthcare Solutions) sold 9,000 shares at $104.16 per share price. On May 25, 2016, David M Weber (Chief Operating Officer) sold 4,342 shares at $97.21 per share price, according to the Form-4 filing with the securities and exchange commission.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.